Diagnosis and treatment of congenital hemophilia with inhibitors. A Latin American perspective

Medicina

Volumn 68, Issue 3, 2008, Pages 227-242

  Bianco, Raul Perez ^a   Ozelo, Margareth Castro ^b   Villaça, Paula Ribeiro ^c   Solano, Maria Helena ^d   Cruz, Guillermo Jimenez ^e   Murillo, Carlos Martinez ^f   Chavez, Jaime Garcia ^f   Mendoza, Saul ^g   Grecco, Ismael Rodriguez ^h   Ruiz Saez, Arlette ⁱ  

^a INST DE INVEST HEMATOLOGICAS   (Argentina)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d HOSPITAL DE SAN JOSÉ   (Colombia)

^e CAJA COSTARRICENSE DE SEGURO SOCIAL   (Costa Rica)

^f INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^g HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS   (Peru)

^h Centro Hospitalario Pereira Rossell   (Uruguay)

ⁱ Centro Nacional de Hemofilia   (Venezuela)

Author keywords

Hemophilia; Hemophilia guidelines; Inhibitors; Treatment

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; ANTIHISTAMINIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; CYCLOPHOSPHAMIDE; HEMOSTATIC AGENT; IMMUNOGLOBULIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; STEROID; TRANEXAMIC ACID;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBODY DETECTION; ANTIBODY TITER; ARTERIAL PRESSURE; ARTICLE; ASSAY; BETHESDA ASSAY; BLEEDING; BRAIN INFARCTION; BRONCHOSPASM; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIARRHEA; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; HEALTH PROGRAM; HEART INFARCTION; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HOME CARE; HUMAN; HYPOTENSION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE PAIN; LOW DRUG DOSE; LUNG EMBOLISM; MIGRAINE; NAUSEA; NEPHROTIC SYNDROME; NIJMEGEN MODIFIED BETHESDA ASSAY; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SOUTH AND CENTRAL AMERICA; SURGICAL PATIENT; THROMBOEMBOLISM; TREATMENT RESPONSE; URTICARIA; VOMITING;

EID: 47649085689     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (118)

1. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
2. Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American study. Haemophilia 1996; 2: 28-31.
3. Goudemand J. Pharmaco-economic aspects of inhibitor treatment. Eur J Haematol 1998; 61: 24-7.
4. World Hemophilia Federation Report on Global Survey 2006. World Federation of Hemophilia, 2007. On www.wfh.org; consulted on 23/04/2008.
5. Rieger A, Roisenberg I. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil. Thromb Haemost 1999; 81: 475-6.
6. Fontes EM, Amorim L, Carvalho SM, Farah MB. Hemophilia care in the state of Rio de Janeiro, Brazil. Rev Panam Salud Pública 2003; 13: 124-8.
7. Izquierdo-Ramírez J, Contreras-Mulato EL, Sotelo-Ham EI et al. Incidence of inhibitors in children with hemophilia A. Bol Med Hosp Infant Méx 1988; 45: 578-82.
8. Boadas A, Ruiz-Sáez A, Arguello A, de Bosch N. Prevalence and acute bleeding treatment of allo and auto FVIII and FIX antibodies cases in Venezuela. Haemophilia 2004; 10: 56.
9. Wight J, Paisley S. The epidemiology of inhibitors in hemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
10. Delivery of treatment for hemophilia. Report of a joint WHO/WFH/ISTH meeting. World Health Organization, 2002.
11. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organization. Br J Haematol 2006; 133: 591-605.
12. Ewing NP, Kasper CK. In vitro detection of mild inhibitors to factor VIII in hemophilia. Am J Clin Pathol 1982; 77: 749-52.
13. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
14. Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the hemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost 1998; 79: 872-5.
15. Verbruggen B, van Heerde W, Novakova I, Lillicrap D, Giles A. A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen modification of the Bethesda factor VIII:C inhibitor assay. Thromb Haemost 2002; 88: 362-4.
16. White GC, II, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
17. Kitchen S, McCraw A. Diagnosis of hemophilia and other bleeding disorders. A laboratory manual. World Federation of Hemophilia, 2000.
18. Available at: http://www.med.unc.edu/isth/. Accessed November 2005.
19. Available at: http://www.wfh.org/. Accessed November 2005.
20. Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haematologica 2000; 85: 7-13.
21. Rossetti LC, Candela M, Pérez Bianco R, de Tezanos Pinto M, Western A, Goodeve A et al. Analysis of factor VIII gene intron 1 inversion in Argentinean families with severe hemophilia A and a review of the literature. Blood Coagul Fibrinolysis 2004;15: 569-72.
22. Santos A, Montalva O, Thomas S, Veiga M, De Paula E, Ozelo M. Genetic and ethnic aspects related to the development of inhibitors among Brazilian patients with hemophilia from five distinct geographical regions in Brazil. Haemophilia 2006; 12: 1-154.
23. Mantilla-Capacho JM, Beltrán-Miranda CP, Luna-Záizar H, et al. Frequency of intron 1 and 22 inversions of Factor VIII gene in Mexican patients with severe Hemophilia A. Am J Hematol 2007; 82: 283-7.
24. Guidelines for the management of hemophilia. World Federation of Hemophilia, 2005.
25. Girolami A, Luzzatto G, Varvarikis C, Pellati D, Sartori R, Girolami B. Main clinical manifestations of a bleeding diathesis: an often disregarded aspect of medical and surgical history taking. Haemophilia 2005; 11: 193-202.
26. Inhibitor Subcommittee of the Association of Hemophilia Clinic Directors of Canada. Suggestions for the management of FVIII inhibitors, revised edition. In: Treatment of Hemophilia Monograph. World Federation of Hemophilia, 2000.
27. Kasper C. Diagnosis and management of inhibitors to factors VIII and IX. In: Treatment of Hemophilia Monograph. World Federation of Hemophilia, 2004.
28. Gringeri A, Mannucci PM; Italian Association of Haemophilia Centres. Italian guidelines for the diagnosis and treatment of patients with hemophilia and inhibitors. Haemophilia 2005; 11: 611-9.
29. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
30. Ingerslev J, Sneppen O, Hvid I, Fredberg U, Kristensen HL, Sindet-Petersen S. Treatment of acute bleeding episodes with rFVIIa. Vox Sang 1999; 77: 42-6.
31. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104: 22-6.
32. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113-9.
33. Astermark J, Donfield SM, DiMichelle DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor - The Feiba® NovoSeven® Comparative Study (FENOC). Blood 2007; 109: 546-51.
34. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 μg kg-1 dose rFVIIa vs. standard 90 μg kg-1 dose rFVIIa and APCC for home treatment of joint bleeds in hemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008, 14: 287-94.
35. Ozelo MC, Villaça PR, De Almeida JO, et al. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with hemophilia and inhibitors in Brazil. Haemophilia 2007;13: 462-9.
36. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 2003; 1: 450-5.
37. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of hemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
38. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G. Home treatment of haemarthroses using single dose regimen of recombinant activated factor VII in patients with hemophilia and inhibitors. A multi-centre, randomized, double blind, cross-over trial. Thromb Haemost 2006; 95: 600-5.
39. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of haemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71
40. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe hemophilia and inhibitors. Haemophilia 2004; 10: 347-51.
41. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. NEJM 1980; 303: 421-5.
42. Teitel J, Berntorp E, Collins P, et al. A systematic approach to controlling problem bleeds in patients with severe congenital hemophilia A and high-titre inhibitors. Haemophilia 2007;13: 256-63.
43. Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with hemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9: 464-520.
44. Ewenstein BM, Takemoto C, Warrier I, et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89: 1115-6.
45. Warrier I, Lenk H, Saidi P, Pollmann H, Tengborn L, Berntorp E. Nephrotic syndrome in hemophilia B patients with inhibitors. Haemophilia 1998; 4: 248.
46. Warrier I. Management of hemophilia B patients with inhibitors and anaphylaxis. Haemophilia 1998; 4: 574-6.
47. Strawczynski H, Stachewitsch A, Morgenstern G, Shaw ME. Delivery of care to hemophilic children: home care versus hospitalization. Pediatrics 1973; 51: 986-91.
48. Rabiner SF, Telfer MC, Fajardo R. Home transfusions of hemophiliacs. JAMA 1972; 221: 885-7.
49. Levine P. The home therapy program at the New England area hemophilia center. Scand J Haematol 1977; 31: 37-51.
50. Soucie JM, Symons J, IV, Evatt B, Brettler D, Huszti H, Linden J. Home-based factor infusion therapy and hospitalization for bleeding complications among males with hemophilia. Haemophilia 2001; 7: 198-206.
51. Solovieva S. Clinical severity of disease, functional disability and health-related quality of life. Three-year follow-up study of 150 Finnish patients with coagulation disorders. Haemophilia 2001; 7: 53-63.
52. Teitel JM, Barnard D, Israels S, Lillicrap D, Poon MC, Sek J. Home management of hemophilia. Haemophilia 2004; 10: 118-33.
53. Ingerslev J, Thykjær H, Scheibel E. Approaches towards successful home treatment in patients with inhibitors. Eur J Haematol 1998: 61: 11-4.
54. Young G, McDaniel M, Nugent DJ. Prophylactic recombinant factor VIIa in hemophilia patients with inhibitors. Haemophilia 2005; 11: 203-7.
55. Saxon BR, Shanks D, Jory CB, Williams V. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. Thromb Haemost 2001; 86: 1126-7.
56. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
57. Hoots WK, Ebbesen LS, Konkle BA, et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of hemophilia patients with inhibitors. Haemophilia 2008; 14: 466-75.
58. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77: 187-93.
59. Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004; 10: 10-6.
60. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with hemophilia A and inhibitors. Haemophilia 2007; 13: 249-55.
61. Villar A, Aronis S, Morfini M, et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven®) in children vs. adults with hemophilia A. Haemophilia 2004; 10: 352-9
62. Klitgaard T, Nielsen TG. Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol 2008; 65: 3-11.
63. Rodriguez-Merchan EC, Rocino A, Ewenstein B, et al. Consensus perspectives on surgery in hemophilia patients with inhibitors: summary statement. Haemophilia 2004; 10: 50-2.
64. Hilgartner MW. Factor replacement therapy. In: Hilgartner MW, Pochedly C (eds): Hemophilia in the Child and Adults. New York, Raven Press Ltd., 1989, pp 1-26.
65. Morris PJ, Wood WG (eds.): Oxford Textbook of Surgery, 2nd edition. Oxford, Oxford University Press, 2000.
66. Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in hemophilia. Haemophilia 1995; 1: 8-13.
67. Shapiro A, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in hemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
68. Hvid I, Rodriguez-Merchan EC. Orthopaedic surgery in haemophilic patients with inhibitors: an overview. Haemophilia 2002; 8: 288-91.
69. Rodriguez-Merchan EC, Rocino A. Literature review of surgery management in inhibitor patients. Haemophilia 2004; 10: 22-9.
70. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
71. Ingerslev J. Efficacy and safety of Recombinant Factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 2000; 26: 425-32.
72. Tjønnfjord GE, Brinch L, Gedde-Dahl T, III, Brosstad FR. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 2004; 10: 174-8.
73. Ingerslev J, Sorensen B. Role of recombinant activated factor VII as hemostatic support in orthopedic surgery. TATM 2006; 8: 35-42.
74. Obergfell A, Auvinen MK, Mathew P. Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: a review of the literature. Haemophilia 2008; 14: 233-41.
75. Ewenstein BM, Valentino LA, Journeycake JM, et al. Consensus recommendations for use of central venous access devices in hemophilia. Haemophilia 2004; 10: 629-48.
76. Morado M, Jimenez-Yuste V, Villar A, et al. Complications of central venous catheters in patients with hemophilia and inhibitors. Haemophilia 2001; 7: 551-6.
77. Bollard CM, Teague LR, Berry EW, Ockelford PA. The use of central venous catheters (portacaths) in children with hemophilia. Haemophilia 2000; 6: 66-70.
78. O'Connell N, Mc Mahon C, Smith J, et al. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with hemophilia and high responding inhibitors. Br J Haematol 2002; 116: 632-5.
79. Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with hemophilia B during major orthopaedic procedures. Haemophilia 2001; 7: 517-22.
80. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698-702.
81. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2: 933.
82. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379-91.
83. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. NEJM 1988; 318: 947-50.
84. Mathias M, Khair K, Hann I, Liesner R. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe hemophilia. Br J Haematol 2004; 125: 366-8.
85. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-8.
86. Carcao M, Ungar WJ, Feldman BM. Cost-utility analysis in evaluating prophylaxis in hemophilia. Haemophilia 2004; 10: 50-7.
87. Curtin J, Misra A, Teo J, Webster B, Lammi A. Use of Rituximab as an alternative strategy for the management of difficult high titre inhibitors in children with hemophilia A. Haemophilia 2004; 10: 57.
88. DiMichele D. Immune tolerance therapy dose as an outcome predictor. Haemophilia 2003; 9: 382-6.
89. Mariani G, Kroner B. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001; 86: 1186-93.
90. DiMichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280-7.
91. Lenk H. The German Registry of immune tolerance treatment in hemophilia-1999 update. Haematologica 2000; 85: 45-7.
92. Haya S, Lopez MF, Aznar JA, Batlle J. Immune tolerance treatment in hemophilia patients with inhibitors: the Spanish Registry. Haemophilia 2001; 7:154-9.
93. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recomendations. Haemophilia 2007; 13: 1-22.
94. Kreuz W, Mentzer D, Auerswald G, Becker S, Joseph-Steiner J. Successful immune tolerance therapy of FVIII inhibitor in children after changing from high to intermediate purity FVIII concentrate. Haemophilia 1996; 2: 19.
95. Rocino A, Papa ML, Salerno E, Capasso F, Miraglia E, de Biasi R. Immune tolerance induction in hemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution. Haemophilia 2001; 7: 33-8.
96. DiMichele D, Rivard G, Hay C, Antunes S. Inhibitors in hemophilia: clinical aspects. Haemophilia 2004; 10: 140-5.
97. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
98. Almeida J, Paula JC, Toscano R. Immune tolerance such as salvage therapy in severe hemophilia A patient with ultra high-responders inhibitors. Haemophilia 2002; 8: 538.
99. Solano MH, Ramírez C, Parra L. Tratamiento de inhibidores del factor VIII en hemofilia. Acta Med Colomb 1998; 23: 193.
100. Carneiro JDA, Bassit RP, Villaça PR, Sandoval EPN, Silva CSSS, D'amico EA. Low-dose immune tolerance induction in hemophilia A children with inhibitors. Haemophilia 2002; 8: 538-9.
101. Wight J. Paisley S, Knight C. Immune tolerance induction in patients with hemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9: 436-63.
102. Tengborg L, Hansson S, Fasth A, Lübeck PO, Berg A, Ljung R. Anaphylactoid reactions and nephrotic syndrome - a considerable risk during factor IX treatment in patients with hemophilia B and inhibitors: a report on the outcome in two brothers. Haemophilia 1998; 4: 854-9.
103. Schulman S. Safety, efficacy and lessons from continuous infusion with rFVIIa. Haemophilia 1998; 4: 564-7.
104. Schulman S. Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring, and cost effectiveness. Semin Thromb Hemost 2000; 26: 421-4.
105. Pruthi RK, Mathew P, Valentino LA, Sumner MJ, Seremetis S, Hoots WK. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in hemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb Haemost. 2007; 98: 726-32.
106. Smith MP, Ludlam CA, Collins PW, et al. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost 2001; 86: 949-53.
107. Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001; 86: 954-8.
108. Mauser-Bunschoten EP, Koopman MM, Goede-Bolder AD, et al. Efficacy of recombinant factor VIIa administered by continuous infusion to hemophilia patients with inhibitors. Haemophilia 2002; 8: 649-56.
109. Ludlam CA, Smith MP, Morfini M, Gringeri A, Santagostino E, Savidge GF. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol 2003; 120: 808-13.
110. Escobar MA. Recombinant Factor VIIa: the possibilities for monitoring. TATM 2003; 5: 51-4.
111. Young G, Ebbesen LS, Viuff D, et al. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in hemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis 2008; 19: 276-82.
112. Lak M, Scharling B, Blemings A, et al. Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram. Haemophilia 2008;14:103-10.
113. Sørensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004; 2: 102-110.
114. Varadi K, Turecek FL, Schwarz HP. Thrombin generation assay and other universal tests for monitoring hemophilia therapy. Haemophilia 2004; 10: 17-21.
115. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
116. Sallah S, Isaksen M, Seremetis S, Payne Rojkjaer L. Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity: a rebuttal. J Thromb Haemost 2005; 3: 820-2.
117. Roberts HR, Monroe DM, III, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41: 101-8.
118. Agency of Health Care Policy and Research. Acute pain management: operative or medical procedures and trauma (Agency of Health Care Policy and Research publications). Clinical Pharmacology 1992; 11: 391-414.